High-grade gliomas, especially glioblastoma (GBM) and others, remain among the most aggressive brain cancers, with few effective treatment options after the tumor recurs. Even with maximal surgical resection, radiotherapy, and chemotherapy, outcomes are poor, underscoring the need for noninvasive, tumor-specific strategies that can spare healthy tissue.
This article was originally published on MedicalXpress.com

